Activation and deactivation of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by cytochrome P450 enzymes and flavin-containing monooxygenases in common marmosets (Callithrix Jacchus)

Drug Metabolism and Disposition

Volumn 43, Issue 5, 2015, Pages 735-742

  Uehara, Shotaro ^a   Uno, Yasuhiro ^b   Inoue, Takashi ^c   Murayama, Norie ^a   Shimizu, Makiko ^a   Sasaki, Erika ^c,d   Yamazaki, Hiroshi ^a  

^a SHOWA PHARMACEUTICAL UNIVERSITY   (Japan)

^b SHIN NIPPON BIOMEDICAL LABORATORIES LTD   (Japan)

^c CENTRAL INSTITUTE FOR EXPERIMENTAL ANIMALS   (Japan)

^d KEIO UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 1,2,3,6 TETRAHYDRO 4 PHENYLPYRIDINE; BENZYDAMINE; BUFURALOL; CYTOCHROME P450; CYTOCHROME P450 1A2; CYTOCHROME P450 2D6; DIMETHYLANILINE MONOOXYGENASE; FLAVIN CONTAINING MONOOXYGENASE 3; QUINIDINE; THIAMAZOLE; UNCLASSIFIED DRUG; 4,6-DINITRO-O-CRESOL; 4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; DIMETHYLANILINE MONOOXYGENASE (N-OXIDE FORMING); DINITRO ORTHO CRESOL; MIXED FUNCTION OXIDASE; OXYGENASE;

ADULT; ANIMAL TISSUE; ARTICLE; BRAIN MICROSOME; CALLITHRIX JACCHUS; CONTROLLED STUDY; DEMETHYLATION; HYDROXYLATION; LIVER MICROSOME; NONHUMAN; OXIDATION; OXYGENATION; PRIORITY JOURNAL; ANALOGS AND DERIVATIVES; ANIMAL; BRAIN; CALLITHRIX; DRUG INACTIVATION; FEMALE; LIVER; MALE; METABOLISM; OXIDATION REDUCTION REACTION; PHYSIOLOGY;

CALLITHRIX JACCHUS; MARMOSETS; PRIMATES;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; ANIMALS; BRAIN; CALLITHRIX; CYTOCHROME P-450 CYP1A2; CYTOCHROME P-450 CYP2D6; CYTOCHROME P-450 ENZYME SYSTEM; DINITROCRESOLS; FEMALE; HYDROXYLATION; INACTIVATION, METABOLIC; LIVER; MALE; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; OXIDATION-REDUCTION; OXYGENASES;

EID: 84940368492     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.115.063594     Document Type: Article

References (33)

1. Abbott DH, Barnett DK, Colman RJ, Yamamoto ME, and Schultz-Darken NJ (2003) Aspects of common marmoset basic biology and life history important for biomedical research. Comp Med 53:339-350.
2. Ando K, Inoue T, and Itoh T (2014) L-DOPA-induced behavioral sensitization of motor activity in the MPTP-treated common marmoset as a Parkinson's disease model. Pharmacol Biochem Behav 127:62-69.
3. Ando K, Obayashi S, Nagai Y, Oh-Nishi A, Minamimoto T, Higuchi M, Inoue T, Itoh T, and Suhara T (2012) PET analysis of dopaminergic neurodegeneration in relation to immobility in the MPTP-treated common marmoset, a model for Parkinson's disease. PLoS One 7:e46371.
4. Bajpai P, Sangar MC, Singh S, Tang W, Bansal S, Chowdhury G, Cheng Q, Fang JK, Martin MV, and Guengerich FP, et al. (2013) Metabolism of 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine by mitochondrion-targeted cytochrome P450 2D6: implications in Parkinson disease. J Biol Chem 288:4436-4451.
5. Ballard PA, Tetrud JW, and Langston JW (1985) Permanent human parkinsonism due to 1- methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP): seven cases. Neurology 35:949-956.
6. Carrion R Jr and Patterson JL (2012) An animal model that reflects human disease: The common marmoset (Callithrix jacchus). Curr Opin Virol 2:357-362.
7. Cashman JR and Ziegler DM (1986) Contribution of N-oxygenation to the metabolism of MPTP (1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine) by various liver preparations. Mol Pharmacol 29:163-167.
8. Chiba K, Horii H, Kubota E, Ishizaki T, and Kato Y (1990) Effects of N-methylmercaptoimidazole on the disposition of MPTP and its metabolites in mice. Eur J Pharmacol 180:59-67.
9. Chiba K, Peterson LA, Castagnoli KP, Trevor AJ, and Castagnoli N Jr (1985) Studies on the molecular mechanism of bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl- 1, 2, 3, 6-tetrahydropyridine. Drug Metab Dispos 13:342-347.
10. Coleman T, Ellis SW, Martin IJ, Lennard MS, and Tucker GT (1996) 1-Methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP) is N-demethylated by cytochromes P450 2D6, 1A2 and 3A4 -implications for susceptibility to Parkinson's disease. J Pharmacol Exp Ther 277: 685-690.
11. Davis KD, Taub E, Houle S, Lang AE, Dostrovsky JO, Tasker RR, and Lozano AM (1997) Globus pallidus stimulation activates the cortical motor system during alleviation of parkinsonian symptoms. Nat Med 3:671-674.
12. Eslamboli A (2005) Marmoset monkey models of Parkinson's disease: which model, when and why? Brain Res Bull 68:140-149.
13. Herraiz T, Guillén H, and Galisteo J (2013) Metabolite profile resulting from the activation/inactivation of 1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine and 2-methyltetrahydrob- carboline by oxidative enzymes. Biomed Res Int 2013:248608.
14. Hichiya H, Kuramoto S, Yamamoto S, Shinoda S, Hanioka N, Narimatsu S, Asaoka K, Miyata A, Iwata S, and Nomoto M, et al. (2004) Cloning and functional expression of a novel marmoset cytochrome P450 2D enzyme, CYP2D30: comparison with the known marmoset CYP2D19. Biochem Pharmacol 68:165-175.
15. Jenner P (2009) From the MPTP-treated primate to the treatment of motor complications in Parkinson's disease. Parkinsonism Relat Disord 15 (Suppl 4):S18-S23.
16. Johansson I and Ingelman-Sundberg M (2011) Genetic polymorphism and toxicology-with emphasis on cytochrome p450. Toxicol Sci 120:1-13.
17. Jones KC and Ballou DP (1986) Reactions of the 4a-hydroperoxide of liver microsomal flavincontaining monooxygenase with nucleophilic and electrophilic substrates. J Biol Chem 261: 2553-2559.
18. Kiyotani K, Shimizu M, Kumai T, Kamataki T, Kobayashi S, and Yamazaki H (2010) Limited effects of frequent CYP2D6∗36-∗10 tandem duplication allele on in vivo dextromethorphan metabolism in a Japanese population. Eur J Clin Pharmacol 66:1065-1068.
19. Langston JW and Ballard PA Jr (1983) Parkinson's disease in a chemist working with 1-methyl- 4-phenyl-1, 2, 5, 6-tetrahydropyridine. N Engl J Med 309:310.
20. Mansfield K (2003) Marmoset models commonly used in biomedical research. Comp Med 53: 383-392.
21. Okano H, Hikishima K, Iriki A, and Sasaki E (2012) The common marmoset as a novel animal model system for biomedical and neuroscience research applications. Semin Fetal Neonatal Med 17:336-340.
22. Shimizu M, Iwano S, Uno Y, Uehara S, Inoue T, Murayama N, Onodera J, Sasaki E, and Yamazaki H (2014) Qualitative de novo analysis of full length cDNA and quantitative analysis of gene expression for common marmoset (Callithrix jacchus) transcriptomes using parallel long-read technology and short-read sequencing. PLoS One 9:e100936.
23. Tokuno H, Moriya-Ito K, and Tanaka I (2012) Experimental techniques for neuroscience research using common marmosets. Exp Anim 61:389-397.
24. Uehara S, Murayama N, Nakanishi Y, Zeldin DC, Yamazaki H, and Uno Y (2011) Immunochemical detection of cytochrome P450 enzymes in liver microsomes of 27 cynomolgus monkeys. J Pharmacol Exp Ther 339:654-661.
25. Uehara S, Murayama N, Yamazaki H, and Uno Y (2010) A novel CYP2A26 identified in cynomolgus monkey liver metabolizes coumarin. Xenobiotica 40:621-629.
26. Uno Y, Iwasaki K, Yamazaki H, and Nelson DR (2011) Macaque cytochromes P450: nomenclature, transcript, gene, genomic structure, and function. Drug Metab Rev 43:346-361.
27. Uno Y, Shimizu M, and Yamazaki H (2013) Molecular and functional characterization of flavincontaining monooxygenases in cynomolgus macaque. Biochem Pharmacol 85:1837-1847.
28. Uno Y, Uehara S, Kohara S, Murayama N, and Yamazaki H (2010) Cynomolgus monkey CYP2D44 newly identified in liver, metabolizes bufuralol, and dextromethorphan. Drug Metab Dispos 38:1486-1492.
29. Uno Y, Uehara S, Kohara S, Murayama N, and Yamazaki H (2014) Polymorphisms of CYP2D17 in cynomolgus and rhesus macaques: An evidence of the genetic basis for the variability of CYP2D-dependent drug metabolism. Drug Metab Dispos 42:1407-1410.
30. Yamazaki H, Nakamura M, Komatsu T, Ohyama K, Hatanaka N, Asahi S, Shimada N, Guengerich FP, Shimada T, and Nakajima M, et al. (2002) Roles of NADPH-P450 reductase and apo- And holo-cytochrome b5 on xenobiotic oxidations catalyzed by 12 recombinant human cytochrome P450s expressed in membranes of Escherichia coli. Protein Expr Purif 24: 329-337.
31. Yamazaki H and Shimizu M (2013) Survey of variants of human flavin-containing monooxygenase 3 (FMO3) and their drug oxidation activities. Biochem Pharmacol 85:1588-1593.
32. Yamazaki M, Shimizu M, Uno Y, and Yamazaki H (2014) Drug oxygenation activities mediated by liver microsomal flavin-containing monooxygenases 1 and 3 in humans, monkeys, rats, and minipigs. Biochem Pharmacol 90:159-165.
33. Yoshihara S, Harada K, and Ohta S (2000) Metabolism of 1-methyl-4-phenyl-1, 2, 3, 6- tetrahydropyridine (MPTP) in perfused rat liver: involvement of hepatic aldehyde oxidase as a detoxification enzyme. Drug Metab Dispos 28:538-543.